Zoetis (ZTS) Capital Expenditures Growth (3y) (2015 - 2026)
Zoetis (ZTS) Capital Expenditures Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 28.56% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 279.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 232.22% |
| Dec 31, 2025 | 2.08% |
| Jun 30, 2025 | 430.15% |
| Mar 31, 2025 | 254.37% |
| Dec 31, 2024 | -26.12% |
| Sep 30, 2024 | -79.67% |
| Jun 30, 2024 | -39.81% |
| Mar 31, 2024 | 260.03% |
| Dec 31, 2023 | 81.14% |
| Sep 30, 2023 | -48.89% |
| Jun 30, 2023 | 404.84% |
| Mar 31, 2023 | 14.47% |
| Dec 31, 2022 | 562.29% |
| Jun 30, 2022 | 26.38% |
| Mar 31, 2022 | -60.11% |
| Dec 31, 2021 | 42.12% |
| Sep 30, 2021 | 17.16% |
| Jun 30, 2021 | 36.83% |
| Mar 31, 2021 | -61.60% |
| Dec 31, 2020 | -567.94% |